Healthcare

  • Can high-priced medicines constitute an abuse of a dominant position in the EU?

    The price of medicines has inevitably always been, and is likely to remain, a long-standing matter of contention between originator companies, governments and patients. It has however become more acute since the launch of some very innovative but very highly priced medicines in recent months, says FTI Consulting’s Darren Kinsella.   Never mind that these…

  • European Commission 2014-2019

    On the 1st November, the 2014-2019 European Commission took office. The new structure, that has been shaped by President Jean-Claude Juncker, consists of seven Vice-Presidents who will steer and coordinate the work of twenty Commissioners. The below overview demonstrates the distribution of responsibilities among the Vice-Presidents and the Commissioners as well as the Heads of…

  • Is the EU moving towards determining healthcare expenditure?

    Something curious is happening with EU health and pharma policies, at a time of the advent of a new European Commission. If one looks at the mission letters of the relevant Commissioners, Vytenis Andriukaitis (Health) and Elżbieta Bieńkowska (Internal Market & Enterprise), the EU health policy agenda is not particularly ambitious. Also, the Commission staff…

Back to top